SPARC signs licensing deal with Visiox for two ophthalmic drug candidates

By on    Pharma Industry News  

SPARC signs licensing deal with Visiox for two ophthalmic drug candidates

Sun Pharma Advanced Research Company (SPARC) has signed a licensing agreement with Visiox Pharma to award exclusive worldwide rights (except for India and Greater China) for developing and commercializing its ophthalmic drug candidates — PDP-716 and SDN-037. As per the terms of the licensing deal, Sun Pharma Advanced Research Company will be entitled to get […]

SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients

By on    Pharma Industry News  

SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients

Sun Pharma Advanced Research Company (SPARC) has succeeded in a phase 3 clinical trial for PDP-716 ophthalmic suspension, its investigational drug for the treatment of open angle glaucoma or ocular hypertension. The late-stage clinical trial met its pre-specified primary endpoint by showing that daily once dosing of PDP-716 is equivalent to Alphagan P 0.1% dosed […]